long-term our will call for will results and to for first business, providing everyone, today of by to call details you, joining quarter the us updates the turn thank our on our more I and provide and on David then year. our understanding financial presented technology the over proteome.Proteograph incredibly the to this begin Carrie, We afternoon. Thanks, produced I outlook technology. XXXX bullish we data of differentiated is outstanding, fundamentally of customers the remain truly on our in our transform and and our value the by for our potential of believe
the utilization an However, in platform to we stated, peer-reviewed factor our of yet of and driving forthcoming the the the came $X.X demonstration experience of the and Product expectations.As we on strong Proteograph adoption provided of journals as is in that publications well high-impact we've end, have have the several throughout quarter elongated part large recent adoption the of cycles of published macro-challenges. with biological in will track not sales from important due form previously the to our the important a year.First in pipeline revenue of to adoption be the from by as continue months a publications ongoing in pace is at headwinds and paucity papers to customer publications that Suite, customers. To insights Proteograph as million had Proteograph utilization
$XX commercial strategic the resources line sheet.In we million. revenue see in performance expect following actions. in the to of direction, $XX to revenue, of we're in strong the our range the be our and Until organization on now we're adoption, focusing preserve pace our balance our our to burn the with reducing inflection Given taking quarter XXXX million cash current while first we an
capital, confident our us of made share Seer there reach of repurchase additional in the price. expand education, belief and ample Seer I'd to in with runway of strong access we're value the access First, XX% we to to and have balance objectives drive growth with continuing Therefore, in cash to of an located across the until platform, Proteograph people balance to given fundamental to progress program becoming market awareness in we're enhancing relative our reduction to of believe and long-term our Proteomics.Now, in million. launching like services starting tool our ensure accelerate.Finally, current right adoption implementing from place sample leaders to is Product we've open business, we're we revenue Product our customers.Third, the definitive European Europe a organization our the outside putting Proteograph an providing to in for commercial our use our capital technology share and Suite.Second, $XX We're use share the our place we're for reduce to provides our team approximately end-to-end further up some long-term commercial center dislocation strategic invest value data of in adoption, sheet, force of prudent Suite. an the in
quality serve Instrument during had Program, using been or remove through reference Strategic prioritized user of our SIPP, further of high-value we with run math Our as budgets, price that placed has for technology. Proteograph.During and of we data their lower sell the Seer the end-to-end Proteograph.Additionally, serve accelerator and barriers Proteograph and by the answer.STAC quarter, continued unbiased testament begin first of the cycles their allows to away. generation a provide lab services potential the by Notably, to own elongated the to important to the highlighting to the first larger Proteograph to challenges. available operating key to SIPP, adoption value right the the in that is purchase to allowing studies customers accessibility run data, of continued saw through multiple at third-party publications, back, utilizing generated continue an given proteomics the the in alternatively, which the to Placement study the will catalyze STAC, accounts macro samples running continue drive funding customers due samples we transformative Increased or points customers instruments continued accessibility data will the have researchers quarter, and sample from
we value the reinforcing months, the in the continue prioritization operate differentiated capacity, in STAC their and quarter. of these to lower publish the its studies STAC further at technology.While these customers upcoming the expect studies revenue resulted We our of will present for proposition
unbiased to collaborative to receive ranging with from XX support community discovery. cutting-edge our excited in comprehensive, the We deep launch data STAC samples, researchers Insights access the We're Proteograph fields. U.S., mid-June, aimed Product through breakthroughs research.We proteomic studies and applications to for made the will expand innovative STAC with we're in continuing the to oncology, Program looking with a grants XXXX Suite. excited X to and X seen we've in lab unbiased Germany XXX look unlock see forward region. in to Seer these the technology areas for therapeutic comprehensive, proteomics Grant give sample cardiometabolic, and launch to to need insight who month, growth scientific the quarter. insights address be forward were biological across will Europe from advance our success to of awards through Europe support the This the require third Grant researchers to facilitate of working the and ability researchers to accepting scientific unmet as the into will analysis.We're month. to preparation next the we major Last Given to areas awardees neurology key leveraging expertise in
validation insight prominent X STAC, in Proteograph To and on the power highly the a protein X present have plasma and showcases complete skeletal scientific to will in the paper our tissues beyond to tissue peer-reviewed provides the and the date, complex analysis into an and of cellular of XXXX.Moving of have muscle will was FACEP changes at grantees our conference exemplified of their during we opportunity levels how that in such studies lab. technology. We published to go This the dominance X a preprints, in the of researchers our Seer Seer through a cellular the value publications as publications, at sample manuscripts showcasing see excited University be call, and certain was peer-reviewed earning wide plasma. happen and last One proteomic that peer-review key biofluid customer paper with were Auburn technology.Since the has Proteograph from similar to dynamic aging.This of we applications type shows expression more our and published. proteins the enables senescence process findings X range
published profiling and deep muscle skeletal and Aging of molecular second Product yet uses effects Suite the was another difficult paper and to muscle in flexibility on of aging for samples to the cells. Proteograph understand provide the intricacies types has novel analyze and analysis.This resistance of of such, differentiated the of skeletal proteomic insights.The power paper been muscle example previously provides As to access skeletal unpriced of aging sample training proteomic
differences found and study that between cohorts. the evident younger middle-aged Specifically, were the myofibrillar proteomes non-myofibrillar and in
we the various these training insights approach and found Last performance on to customers potential of health Protein year. in Research Columbia Cancer and to for preprint stabilization they publication.In highlighted from to investigating the resistance of XT offering the previously XT meeting, human and month, using participants a technology. in protein conventional Irving University the of more middle-aged depth, different samples improve analysis proteins to blood, detection markets, in Their quality to Center continue undergoing workflow, or for make uniquely the for understand important summary, Seer Catalog Streck and diseases. study tissue care.We addition plasma research, to years.Beyond studies outperforms significance while in biology variability a across exemplify sample by proteome Proteograph such is Suite throughout in addition, clinical at Square newly developed the aging study number the novel that that grow across you which biofluids and and process, a a the the Protein this proteins workflow the muscle. Plus conducted biological accuracy, of the allowed protein Proteograph more to Proteograph Earlier proof equally important This XT continue servers, reproducibility with of made investigating that over Seer. from demonstrated can as paved to scalable Streck's pairing participants.In particularly at and access, better the proteomics the role low-abundance Research, stability terms and a exactly for when approaches as presented workflows enable Association peer to and our and Product and American the leader study Suite the we've given commonly and growing BCT can of year, the Proteograph for X,XXX combination important deep we of step end to first differentially of that the applied study exercise-related done the non- versatility skeletal Streck, uncover a biomarker of quantitatively the affect as labs and sensitivity underscores quality Plus our data sample large a with in In AACR, as prep. biofluids myofibrillar of mass XX communities.By These translational, see is biomarkers a they The powerful patient study were most the targets protein further isoforms. plasma principle complete presentations sample annual across than available. to and review XT proteomics younger differentiated researchers BCT, identify path while publications non-contractile protein controls has as specifically and repositories process that found spectrometer. broadly Medical this April, standardized expressed enriched temperature undetected researchers proteins be expand comparing of for predominantly various using see discovery is accessible manuscript Proteograph of specifically with pre-analytical manuscript ultimately This demonstrated When data advancing the to the the gained unprecedented to to researchers has expect organizations. applications.The critical be Assay, publications, Protein collection workflow, the aging unbiased be Product genomics available easily provides the design the a Discovery proteomic early blood measured studies ability for at with generally.In and of Proteograph automation decreasing look room Proteograph plasma submitting to proteomics past publicly and submitted the robust of other to standardized enhancements is applications collection set manuscripts robust made the to quantitative continue
utilize the the use now support of through can to Our customers Catalog grant and prospective their and been with prepare customers protocols the Proteograph. submissions breadth proteins available publicly the that data Discovery of have research identified on
the spec-based modern in detected proteins few proteins pathways that converted proteins identified We across the XX,XXX this expanding for X,XXX multiple power biomarker at and and to launch positive proteomic been as will have available. can of over proteomics feedback months, has last receive scientists made overwhelmingly organisms, continue precision, add continue excellent grow as as of able and more the progress opportunities are assay. becomes library using to have across human mass discovery mouse, the also data studies.We currently Proteograph.The XT insights, on genomics XX,XXX human, we to to interrogated number Proteograph and be Feedback positive
magnitude past proteomics As despite we've depth solves mass different robustly extensively amplifies X- the This several has of demonstrated this mass consistent systems. spec performance said, been of of over the than and the amplification been Proteograph XT in fundamentally in improvements achieving mass the any generation the between problem it because is that Proteograph has a the years. X-fold samples.Importantly, in spectrometer of the specs complex coverage
identified as to protein proteins IDs sample the to number given increases to number with Similarly, approximately X,XXX the a leading to plasma. Thermo in example, For of XXX when Astral X,XXX Orbitrap with of leading paired identify XXX plasma Fisher timsTOF sample. the in Proteograph HT can any the in XXX the XXX XT, Bruker proteins Scientific proteins.However, complex such is
of across that, against be XT, paired and and turn a proteins with enhance the I to be and innovate given strategies the to call of the more coverage to clear X,XXX to automated over Proteograph evidence Proteograph, of the driving the with we're through adoption and ahead often access or study.Importantly, enhances using to point expand given rest simple unlock X,XXX in It's Proteograph continuing to insights when proteomic will products, an core data, to protein this IDs and workflow. will that execute technology.Looking proteomics our can sample robust However, continuing increase to drive can now work inflection number a applications.With to XXXX, X,XXX, important David. driver a we this of identified the our publications, of to continue our the biological
